Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension
American Journal of Hypertension · 2024
DOI: 10.1093/ajh/hpae038 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hypertension, 2024. Verfasst von Xuelin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Souther…. Hauptthemen laut MEDLINE: Valsartan, Aminobutyrates, Drug Combinations, Biphenyl Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Chinese Cardiovascular Association, Natural Science Foundation of Guangdong, China, China Heart House-Chinese Cardiovascular Association.
Abstract (Originalsprache)
BACKGROUND Optimal antihypertensive medication for chronic type B aortic dissection (AD) remains undecided. This study compared the efficacy and safety of sacubitril/valsartan with valsartan to determine suitable antihypertensive drug combinations. METHODS In this single-center, open-label, randomized, controlled trial, patients with chronic Stanford type B AD and mild hypertension were randomized to receive sacubitril/valsartan 100/200 mg or valsartan 80/160 mg. The primary endpoint was the reduction in mean sitting systolic blood pressure (msSBP) at week 8 in patients with sacubitril/valsartan vs. valsartan. Key secondary endpoints included changes in (i) mean sitting diastolic blood pressure (msDBP); (ii) pulse pressure (PP); and (iii) mean ambulatory blood pressure (BP) for 24-hour, daytime, and nighttime. Safety assessments included adverse events (AEs) and serious AEs. This trial was registered with the Chinese Clinical Trial Registry, identifier: ChiCTR2300073399. RESULTS A total of 315 patients completed the study. Sacubitril/valsartan provided a significantly greater reduction in msSBP than valsartan at week 8 (between-treatment difference: −5.1 mm Hg [95% confidence interval −5.8 to −4.5], P < 0.001). Reductions in msSBP, msDBP, and PP as well as the mean ambulatory BP for 24-hour, daytime, and nighttime, were significantly greater in sacubitril/valsartan compared with valsartan (all P < 0.001). No excessive episodes of AEs occurred in the sacubitril/valsartan group. CONCLUSIONS Sacubitril/valsartan and valsartan reduced BP compared with baseline values. However, sacubitril/valsartan improved BP control to a greater extent than valsartan. It may offer a new treatment option for patients with mild hypertension and chronic type B AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
- Shantou University Medical College, Shantou, Guangdong, China.
- Department of Emergency Medicine, Emergency Intensive Care Unit, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
ORCID-Profile: Xuyu He
Förderung
- Chinese Cardiovascular Association
- Natural Science Foundation of Guangdong, China
- China Heart House-Chinese Cardiovascular Association
Zitieren
APA
Wang, X., Song, F., Jiang, L., Huang, Z., Luo, S., Li, X., & He, X. (2024). Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpae038
Vancouver
Wang X, Song F, Jiang L, Huang Z, Luo S, Li X, et al. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension. American Journal of Hypertension. 2024. doi:10.1093/ajh/hpae038
BibTeX
@article{Wang2024,
author = {Wang, Xuelin and Song, Feier and Jiang, Lujing and Huang, Ziling and Luo, Songyuan and Li, Xin and He, Xuyu},
title = {Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension},
journal = {American Journal of Hypertension},
year = {2024},
doi = {10.1093/ajh/hpae038}
}
EUVIMED